Wincap Financial LLC Purchases 126 Shares of AbbVie Inc. (NYSE:ABBV)

Wincap Financial LLC grew its position in AbbVie Inc. (NYSE:ABBV) by 1.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,695 shares of the company’s stock after acquiring an additional 126 shares during the period. AbbVie accounts for 1.7% of Wincap Financial LLC’s portfolio, making the stock its 12th largest holding. Wincap Financial LLC’s holdings in AbbVie were worth $1,822,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. New Republic Capital LLC increased its position in AbbVie by 3.2% in the 1st quarter. New Republic Capital LLC now owns 3,814 shares of the company’s stock valued at $799,000 after acquiring an additional 120 shares in the last quarter. Foundations Investment Advisors LLC grew its stake in shares of AbbVie by 8.8% during the first quarter. Foundations Investment Advisors LLC now owns 22,567 shares of the company’s stock valued at $4,728,000 after purchasing an additional 1,828 shares during the last quarter. KFA Private Wealth Group LLC increased its holdings in shares of AbbVie by 8.3% in the first quarter. KFA Private Wealth Group LLC now owns 2,095 shares of the company’s stock valued at $439,000 after purchasing an additional 160 shares in the last quarter. Schubert & Co bought a new position in AbbVie in the 1st quarter worth approximately $241,000. Finally, Oxler Private Wealth LLC raised its position in AbbVie by 0.8% in the 1st quarter. Oxler Private Wealth LLC now owns 16,855 shares of the company’s stock worth $3,531,000 after purchasing an additional 140 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Price Performance

ABBV stock opened at $190.22 on Monday. The stock has a 50-day moving average price of $187.62 and a two-hundred day moving average price of $189.85. AbbVie Inc. has a 1 year low of $163.81 and a 1 year high of $218.66. The stock has a market cap of $336.00 billion, a PE ratio of 80.94, a price-to-earnings-growth ratio of 1.25 and a beta of 0.48. The company has a current ratio of 0.76, a quick ratio of 0.64 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.40 by $0.06. AbbVie had a return on equity of 412.03% and a net margin of 7.31%. The business had revenue of $13.34 billion during the quarter, compared to the consensus estimate of $12.91 billion. During the same period last year, the company earned $2.31 earnings per share. AbbVie’s quarterly revenue was up 8.4% on a year-over-year basis. Equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be given a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a yield of 3.45%. The ex-dividend date of this dividend is Tuesday, July 15th. AbbVie’s dividend payout ratio (DPR) is currently 279.15%.

Analyst Ratings Changes

A number of brokerages have commented on ABBV. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 22nd. Bank of America raised their price target on AbbVie to $204.00 and gave the company a “hold” rating in a report on Monday, June 9th. Guggenheim boosted their price objective on AbbVie from $214.00 to $216.00 and gave the stock a “buy” rating in a report on Tuesday, April 29th. Morgan Stanley upped their target price on shares of AbbVie from $241.00 to $250.00 and gave the company an “overweight” rating in a research report on Monday, April 28th. Finally, Citigroup lifted their price target on shares of AbbVie to $205.00 and gave the stock a “hold” rating in a research report on Wednesday, June 11th. Eight equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $211.29.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.